Mary Hobart

Mary Hobart's Title

Mary Hobart holds the prestigious position of Vice President, Global Regulatory Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). In this role, she spearheads the global medical and regulatory strategy, ensuring that the company's products meet all regulatory requirements across different markets. Her position is pivotal in navigating the complex landscape of pharmaceutical regulations, which is critical for the successful development and commercialization of new drugs.

Mary Hobart's Experience

With over 25 years of experience in clinical, academic, pharmaceutical medicine, and drug development, Mary Hobart brings a wealth of expertise to her role at OPDC. Her extensive background encompasses various facets of the healthcare and pharmaceutical industries, allowing her to provide valuable insights and leadership. Her experience ensures that OPDC's regulatory strategies are not only compliant with international standards but also innovative and forward-thinking.

Mary Hobart's Company

Mary Hobart is a key executive at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), a subsidiary of Otsuka Holdings Co., Ltd. OPDC is known for its dedication to innovative solutions in the fields of neuroscience, oncology, and cardiovascular health. Under Mary's leadership in regulatory affairs, the company continues to advance its mission of delivering new and effective treatments to patients worldwide, navigating the intricacies of global regulatory environments.

Mary Hobart's Achievements

Throughout her illustrious career, Mary Hobart has played a crucial role in the successful approval and commercialization of numerous pharmaceutical products. Her strategic approach to regulatory affairs has ensured that these products not only comply with stringent regulatory standards but also reach the market in a timely manner. Her achievements include leading regulatory submissions, managing complex clinical trials, and contributing to the development of groundbreaking therapies that address unmet medical needs.